Travere Therapeutics annual operating margin
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Travere Therapeutics's operating margin was −12.80% for fiscal 2025.
View full Travere Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −12.80% | +126.08 pp |
| 2024 | 2024-12-31 | −138.88% | +128.37 pp |
| 2023 | 2023-12-31 | −267.24% | +24.93 pp |
| 2022 | 2022-12-31 | −292.17% | −140.91 pp |
| 2021 | 2021-12-31 | −151.27% | −62.44 pp |
| 2020 | 2020-12-31 | −88.83% | −10.49 pp |
| 2019 | 2019-12-31 | −78.34% | −29.61 pp |
| 2018 | 2018-12-31 | −48.73% | −14.01 pp |
| 2017 | 2017-12-31 | −34.72% | +8.86 pp |
| 2016 | 2016-12-31 | −43.58% | +7.23 pp |
| 2015 | 2015-12-31 | −50.80% | +232.17 pp |
| 2014 | 2014-12-31 | −282.98% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 2.33% | +13.38 pp |
| Q1 2026 | 2026-03-31 | −29.02% | +23.19 pp |
| Q4 2025 | 2025-12-31 | −25.01% | +56.21 pp |
| Q3 2025 | 2025-09-30 | 15.12% | +104.39 pp |
| Q2 2025 | 2025-06-30 | −11.05% | +114.06 pp |
| Q1 2025 | 2025-03-31 | −52.21% | +284.32 pp |
| Q4 2024 | 2024-12-31 | −81.21% | +127.92 pp |
| Q3 2024 | 2024-09-30 | −89.27% | +160.32 pp |
| Q2 2024 | 2024-06-30 | −125.11% | +197.76 pp |
| Q1 2024 | 2024-03-31 | −336.53% | −21.30 pp |
| Q4 2023 | 2023-12-31 | −209.13% | +86.39 pp |
| Q3 2023 | 2023-09-30 | −249.59% | +44.64 pp |
| Q2 2023 | 2023-06-30 | −322.87% | −48.63 pp |
| Q1 2023 | 2023-03-31 | −315.23% | −7.78 pp |
| Q4 2022 | 2022-12-31 | −295.52% | — |
| Q3 2022 | 2022-09-30 | −294.23% | −247.74 pp |
| Q2 2022 | 2022-06-30 | −274.24% | −209.58 pp |
| Q1 2022 | 2022-03-31 | −307.45% | −207.15 pp |
| Q3 2021 | 2021-09-30 | −46.49% | −8.48 pp |
| Q2 2021 | 2021-06-30 | −64.66% | −16.94 pp |
| Q1 2021 | 2021-03-31 | −100.30% | −68.76 pp |
| Q4 2020 | 2020-12-31 | −232.53% | −172.20 pp |
| Q3 2020 | 2020-09-30 | −38.00% | +39.60 pp |
| Q2 2020 | 2020-06-30 | −47.72% | +33.99 pp |
| Q1 2020 | 2020-03-31 | −31.54% | +65.07 pp |
| Q4 2019 | 2019-12-31 | −60.33% | −48.94 pp |
| Q3 2019 | 2019-09-30 | −77.61% | +9.81 pp |
| Q2 2019 | 2019-06-30 | −81.71% | −29.55 pp |
| Q1 2019 | 2019-03-31 | −96.61% | −50.00 pp |
| Q4 2018 | 2018-12-31 | −11.39% | +24.60 pp |
| Q3 2018 | 2018-09-30 | −87.41% | −61.12 pp |
| Q2 2018 | 2018-06-30 | −52.16% | −17.11 pp |
| Q1 2018 | 2018-03-31 | −46.61% | −3.75 pp |
| Q4 2017 | 2017-12-31 | −35.98% | +12.83 pp |
| Q3 2017 | 2017-09-30 | −26.30% | +33.72 pp |
| Q2 2017 | 2017-06-30 | −35.05% | −0.89 pp |
| Q1 2017 | 2017-03-31 | −42.86% | −14.45 pp |
| Q4 2016 | 2016-12-31 | −48.82% | +1.12 pp |
| Q3 2016 | 2016-09-30 | −60.01% | +13.17 pp |
| Q2 2016 | 2016-06-30 | −34.16% | −5.31 pp |
| Q1 2016 | 2016-03-31 | −28.41% | +18.24 pp |
| Q4 2015 | 2015-12-31 | −49.94% | +82.81 pp |
| Q3 2015 | 2015-09-30 | −73.19% | +188.76 pp |
| Q2 2015 | 2015-06-30 | −28.85% | +270.38 pp |
| Q1 2015 | 2015-03-31 | −46.65% | +78746.21 pp |
| Q4 2014 | 2014-12-31 | −132.74% | — |
| Q3 2014 | 2014-09-30 | −261.94% | — |
| Q2 2014 | 2014-06-30 | −299.23% | — |
| Q1 2014 | 2014-03-31 | −78,792.86% | — |
Over the last five fiscal years, Travere Therapeutics's operating margin increased from −88.83% to −12.80%, a change of +76.03 percentage points. The latest reported quarter, Q2 2026, shows 2.33%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Travere Therapeutics source filings ↗